It's about a real-life response to AIDS - a fierce commitment to creating and translating knowledge that advances the fight against HIV & AIDS
- This event has passed.
Research on Nucleotide Analogues Leads to Major Advancements in Antiviral Therapy
September 16, 2016 @ 8:30 am - 9:30 am
A talk by John C. Martin, PhD
Executive Chairman
Gilead Sciences
Sept. 16, 2016
8:30 – 9:30 a.m.
1131 Bioinformatics
UNC Campus (directions)
John C. Martin, PhD, joined Gilead Sciences in 1990 and was appointed Executive Chairman in March 2016. He served as Chairman and Chief Executive Officer from June 2008 through March 2016 and President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago, an MBA from Golden Gate University and a BS in chemical engineering from Purdue University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
